Read by QxMD icon Read

Clinical Colorectal Cancer

Jeffrey L Turner, Joshua Reardon, Tanios Bekaii-Saab, Spero R Cataland, Matthew J Arango
No abstract text is available yet for this article.
September 20, 2016: Clinical Colorectal Cancer
Jordan Axelrad, Anuja Kriplani, Umut Ozbek, Noam Harpaz, Jean-Frederic Colombel, Steven Itzkowitz, Randall F Holcombe, Celina Ang
BACKGROUND: Inflammatory bowel disease (IBD), comprising Crohn disease and ulcerative colitis, is a risk factor for colorectal cancer (CRC). Chemotherapy toxicity may exacerbate IBD symptoms and vice versa, but data are limited. We evaluated chemotherapy tolerance and oncologic outcomes in patients with CRC with and without IBD. PATIENTS AND METHODS: Medical records of patients with CRC with and without IBD treated between 2008 and 2013 were reviewed. Where possible, patients were matched by age, sex, stage, and diagnosis year...
September 20, 2016: Clinical Colorectal Cancer
Felice N van Erning, Maryska L G Janssen-Heijnen, Johannes A Wegdam, Gerrit D Slooter, Jan H Wijsman, Art Vreugenhil, Tonneke A J M Beijers, Lonneke V van de Poll-Franse, Valery E P P Lemmens
INTRODUCTION: Among the elderly, the impairment of functional capacities due to neuropathy can have a significant impact. The aim of the present study was to investigate the course of neuropathic symptoms among elderly patients with stage III colon cancer treated with CAPOX (capecitabine, oxaliplatin), capecitabine monotherapy, or no adjuvant chemotherapy. MATERIALS AND METHODS: The Netherlands Cancer Registry was used to select patients with stage III colon cancer and aged ≥ 70 years...
September 17, 2016: Clinical Colorectal Cancer
Ben Y Zhang, Jeremy C Jones, Andrew M Briggler, Joleen M Hubbard, Benjamin R Kipp, Daniel J Sargent, Jesse G Dixon, Axel Grothey
BACKGROUND: Although the lack of CDX2 expression has recently been proposed as a potential biomarker for a high risk of relapse in patients with stage II and III colon cancer after complete surgical resection, its prognostic role in metastatic colorectal cancer (CRC) remains unclear and warrants investigation. MATERIALS AND METHODS: We identified 145 patients treated at our institution from 2006 to 2016, including 66 patients with CDX2-negative metastatic CRC and a comparison cohort of 79 patients with CDX2-positive metastatic CRC...
September 17, 2016: Clinical Colorectal Cancer
Finn Ole Larsen, Alice Markussen, Benny V Jensen, Anne L Fromm, Kirsten K Vistisen, Vibeke K Parner, Dorte Linnemann, Rasmus H Hansen, Helle H Johannesen, Jakob V Schou
PURPOSE: To evaluate the effect of capecitabine and oxaliplatin before, during, and after radiotherapy for high-risk rectal cancer. PATIENTS AND METHODS: Patients with rectum cancer T4 or T3 involving the mesorectal fascia was included in a prospective phase 2 trial. Liver or lung metastases were accepted if the surgeons found them resectable. The patients received 6 weeks of capecitabine and oxaliplatin before chemoradiotherapy (CRT), continued capecitabine and oxaliplatin during radiotherapy, and received 4 weeks of capecitabine and oxaliplatin after CRT...
September 14, 2016: Clinical Colorectal Cancer
Carmine Pinto, Lorenzo Antonuzzo, Luca Porcu, Giuseppe Aprile, Evaristo Maiello, Gianluca Masi, Fausto Petrelli, Mario Scartozzi, Valter Torri, Sandro Barni
BACKGROUND: Whether bevacizumab represents a feasible option for the first-line treatment of unfit and elderly patients with metastatic colorectal cancer (mCRC) remains controversial. The present systematic review and meta-analysis evaluated the efficacy and safety data of bevacizumab combined with first-line fluoropyrimidine monochemotherapy for these complex patients. PATIENTS AND METHODS: A systematic search of the published data was conducted through May 31, 2016...
August 31, 2016: Clinical Colorectal Cancer
Toshiki Masuishi, Hiroya Taniguchi, Satoshi Hamauchi, Azusa Komori, Yosuke Kito, Yukiya Narita, Takahiro Tsushima, Makoto Ishihara, Akiko Todaka, Tsutomu Tanaka, Tomoya Yokota, Shigenori Kadowaki, Nozomu Machida, Takashi Ura, Akira Fukutomi, Masashi Ando, Yusuke Onozawa, Masahiro Tajika, Hirofumi Yasui, Kei Muro, Keita Mori, Kentaro Yamazaki
BACKGROUND: Regorafenib and trifluridine/tipiracil (TAS-102) both prolong survival for patients with refractory metastatic colorectal cancer. However, it is unclear which drug should be administered first. MATERIALS AND METHODS: We retrospectively evaluated the data from patients who had received regorafenib or TAS-102 at 2 institutions from May 2013 to March 2015. The inclusion criteria were disease refractory or intolerant to fluoropyrimidines, oxaliplatin, irinotecan, anti-vascular endothelial growth factor antibodies, and anti-epidermal growth factor receptor (EGFR) antibodies (if KRAS exon 2 wild-type), and no previous treatment with regorafenib or TAS-102...
August 31, 2016: Clinical Colorectal Cancer
Adriana Romiti, Eliana Rulli, Emanuela Pilozzi, Chiara Gerardi, Michela Roberto, Lorenzo Legramandi, Rosa Falcone, Ilaria Pacchetti, Paolo Marchetti, Irene Floriani
BACKGROUND: Many studies have disclosed the prognostic effect of microsatellite instability (MSI) and/or loss of mismatch repair proteins in colorectal cancer. Nevertheless, little evidence supports their role in the decision-making of adjuvant therapy for patients with stage II disease. MATERIALS AND METHODS: The aim of this systematic review was to evaluate the prognostic and/or predictive role of MSI status in patients with stage II colorectal cancer on disease-free survival and overall survival...
August 31, 2016: Clinical Colorectal Cancer
Rémy Kinj, Pierre-Yves Bondiau, Eric François, Jean-Pierre Gérard, Arash O Naghavi, Axel Leysalle, Emmanuel Chamorey, Ludovic Evesque, Bernard Padovani, Antoine Ianessi, Karen Benezery, Jérôme Doyen
INTRODUCTION: Patients with metastatic colorectal cancer (CRC) may present with oligometastatic lung lesions for which stereotactic ablative radiotherapy (SABR) can be utilized. This study aims to report efficacy and prognostic factors associated with colorectal lung metastases treated with SABR. MATERIAL AND METHODS: This is a retrospective study including patients who presented with lung oligometastasis from CRC treated with SABR from September 2007 to November 2014...
August 31, 2016: Clinical Colorectal Cancer
Manish Bhandare, Prachi Patil, Vishwas Pai, Rahul Bhamre, Reena Engineer, Vikas Ostwal, Avanish Saklani
BACKGROUND: Peritoneal carcinomatosis (PC) from colorectal cancers (CRC) either at initial presentation or at subsequent recurrence presents a significant treatment challenge. The aim of our study was to find its incidence and analyze outcomes of patients with PC from CRC origin managed by different treatment modalities. PATIENTS AND METHODS: A retrospective analysis of patients, from August 2013 to July 2014, presenting with metastatic peritoneal disease from CRC with or without metastasis to other sites was performed...
August 30, 2016: Clinical Colorectal Cancer
Matthew Chan, Kiara Hugh-Yeun, Gillian Gresham, Caroline H Speers, Hagen F Kennecke, Winson Y Cheung
BACKGROUND: We compared the patterns and factors associated with chemotherapy and bevacizumab use in elderly versus young patients with metastatic colon cancer (mCC) and determined the effect of systemic therapy on overall survival (OS) according to age. MATERIALS AND METHODS: Patients diagnosed with mCC from 2009 to 2010 in British Columbia, Canada were reviewed and categorized as elderly patients (age ≥ 70 years) and young patients (age < 70 years). Cox regression models adjusted for age and confounders were used to determine the effect of systemic therapy on OS...
August 30, 2016: Clinical Colorectal Cancer
Dincer Aydin, Mehmet Ali Sendur, Umut Kefeli, Olcun Umit Unal, Didem Tastekin, Murat Akyol, Eda Tanrikulu, Aydin Ciltas, Basak Bala Ustaalioglu, Mukremin Uysal, Onur Esbag, Dogan Yazilitas, Ozgur Tanrıverdi, Ahmet Bilici, Erkan Arpaci, Veli Berk, Tarkan Yetisyigit, Nuriye Yildirim Ozdemir, Ilhan Oztop, Ahmet Alacacioglu, Ozhan Aydin, Melike Ozcelik, Emre Yildirim, Nur Dinc, Mahmut Gumus
BACKGROUND: Small bowel adenocarcinoma (SBA) is a rare tumor of the gastrointestinal system with poor prognosis. Because these are rarely encountered tumors, the aim of this multicenter study was evaluation of prognostic factors and adjuvant chemotherapy in patients with curatively resected SBA. MATERIALS AND METHODS: A total of 78 patients diagnosed with curatively resected SBA were involved in the retrospective study. Forty-eight patients received 1 of 3 different chemotherapy regimens, whereas 30 patients did not receive any adjuvant treatment...
August 30, 2016: Clinical Colorectal Cancer
Richard Lee-Ying, Brandon Bernard, Gillian Gresham, Leo Chen, Caroline Speers, Hagen F Kennecke, Howard John Lim, Winson Y Cheung, Daniel John Renouf
BACKGROUND: Metastatic resection (MR) of liver-limited disease is an effective therapy for selected patients with metastatic colorectal cancer (mCRC). Despite limited data, this approach has been expanded to include MR of other sites, such as the lung, locoregional, and other distant disease (ODD). We performed a population-based study of patients with mCRC who had undergone MR and compared survival between MR of the liver and MR of other sites. METHODS: Patients with mCRC who were referred to the British Columbia Cancer Agency between 1995 and 2010 were reviewed...
August 9, 2016: Clinical Colorectal Cancer
María Arriba, Ricardo Sánchez, Daniel Rueda, Laura Gómez, Juan L García, Yolanda Rodríguez, José Antonio Pajares, Jessica Pérez, Miguel Urioste, Rogelio González Sarmiento, José Perea
BACKGROUND: Two or more primary colorectal tumors coexisting at the time of diagnosis are considered to be synchronous tumors. It is estimated that synchronous colorectal cancer (SCRC) only accounts for 1.1% to 8.1% of all colorectal cancers (CRCs), and its molecular basis is still poorly understood. PATIENTS AND METHODS: We evaluated the microsatellite instability (MSI) and the CpG island methylator phenotype (CIMP) statuses in a series of 49 patients (98 tumors) diagnosed with sporadic SCRC at the 12 de Octubre University Hospital with the aim of improving the molecular characterization of this type of tumor...
August 9, 2016: Clinical Colorectal Cancer
Lindsay A Renfro, Nan Zhang, Margarita Lopatin, Calvin Chao, Steven R Alberts
BACKGROUND: The Oncotype DX colon cancer assay is a validated predictor of recurrence risk in patients with resected stage II colon cancer. We previously reported that Oncotype DX led to a change in treatment recommendations for 45% of patients with T3 mismatch repair proficient (MMR-P) stage II tumors in a prospective study. In the present study, we report the assay's influence on patient treatment decisions, physician confidence, concordance between physicians and patients, and patient decisional conflict...
August 9, 2016: Clinical Colorectal Cancer
Stefano Kim, Anne Cayre, Marine Jary, Marion Jacquin, Francine Arbez-Gindre, Francine Fein, Zaher Lakkis, Thierry Nguyen, Christophe Borg
No abstract text is available yet for this article.
August 9, 2016: Clinical Colorectal Cancer
Lore Decoster, Leen Vanacker, Cindy Kenis, Hans Prenen, Erik Van Cutsem, Jacques Van Der Auwera, Ellen Van Eetvelde, Katrien Van Puyvelde, Johan Flamaing, Koen Milisen, Jean Pierre Lobelle, Jacques De Grève, Hans Wildiers
INTRODUCTION: This study aims to evaluate the relevance of geriatric assessment (GA) in older patients with colorectal cancer (CRC) and to study functional status (FS) and chemotherapy-related toxicity during treatment. METHODS: Patients with CRC aged ≥ 70 years were evaluated at baseline using a GA. Results were communicated to the treating physician. At 2 to 3 months follow-up, FS was reassessed, and chemotherapy-related toxicity was recorded. RESULTS: A total of 193 patients, with a median age of 77 years, were included...
August 8, 2016: Clinical Colorectal Cancer
Michael Pishvaian, Michael A Morse, Jennifer McDevitt, Jonathan D Norton, Song Ren, Gabriel J Robbie, Patricia C Ryan, Serguei Soukharev, Haifeng Bao, Crystal S Denlinger
INTRODUCTION: MEDI-565, a bispecific, single-chain antibody targeting human carcinoembryonic antigen on tumor cells and the CD3 epsilon subunit of the human T-cell receptor complex, showed antitumor activity in carcinoembryonic antigen-expressing tumors in murine models. PATIENTS AND METHODS: This phase I, multicenter, open-label dose escalation study enrolled adults with gastrointestinal adenocarcinomas. MEDI-565 was given intravenously over 3 hours on days 1 through 5 in 28-day cycles, with 4 single-patient (0...
August 4, 2016: Clinical Colorectal Cancer
Riccardo Giampieri, Angelo Restivo, Valeria Pusceddu, Michela Del Prete, Elena Maccaroni, Alessandro Bittoni, Luca Faloppi, Kalliopi Andrikou, Maristella Bianconi, Francesco Cabras, Rossana Berardi, Luigi Zorcolo, Francesco Scintu, Stefano Cascinu, Mario Scartozzi
BACKGROUND: The potential clinical impact of aspirin use beyond its canonical indications is a novel matter of scientific debate. In patients with metastatic colorectal cancer failing all available options, regorafenib and TAS 102 represent the only chance of treatment. Although effective, these therapeutic options bring along a not-negligible burden in terms of economic costs and toxicity. In this setting, the indication to use aspirin in combination with chemotherapy would potentially represent a medical revolution under the economic and toxicity profile...
August 4, 2016: Clinical Colorectal Cancer
Viviane Hess, Ralph Winterhalder, Roger von Moos, Lucas Widmer, Priska Stocker, Monika Jermann, Richard Herrmann, Dieter Koeberle
BACKGROUND: The risk/benefit ratio of any treatment can only be fully assessed if long-term results of both efficacy and toxicity are taken into account. Whereas the combined modality treatment of locally advanced rectal cancer (LARC) has considerably improved prognosis, particularly with regard to local control, long-term results-including patient-reported outcomes-are underreported. PATIENTS AND METHODS: Patients with LARC treated within a multicenter single-arm phase II study were prospectively assessed for at least 5 years after surgery...
July 30, 2016: Clinical Colorectal Cancer
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"